HomeBUSINESS
BUSINESS

Patient Enrollment Completed in Japan PIII Study of Diabetes Treatment Imeglimin: Poxel
(Oct.10.2018)

French biopharma Poxel announced on October 9 that patient enrollment has been completed in a Japan PIII study to assess the efficacy and safety of imeglimin in Japanese patients with type 2 diabetes ...
(LOG IN FOR FULL STORY)